Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Rapastinel

Home DrugsRapastinel

Investigational

Small Molecule

Rapastinel

Unknown Manufacturer

Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).

Technical identifiers

Chemical Formula: C₁₈H₃₁N₅O₆
CAS Number: 117928-94-6
UNII ID: 6A1X56B95E

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
CN 108601814 AApplicant: UNIV NORTHWESTERNPriority: 2015
CN
NMDA RECEPTOR MODULATORS (RAPASTINEL) COMBINATION FOR USE IN COMBINED TREATMENT (SLEEP AND CNS DISORDER)
CN 111670041 AApplicant: NAUREX INCPriority: 2017
CN
SALT AND CRYSTALLINE FORMS OF RAPASTINEL
CN 113557028 AApplicant: NAUREX INCPriority: 2019
CN